Archival ReportSafety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
Section snippets
Participants
Participants were patients with chronic or recurrent MDD, as per the Structured Clinical Interview for DSM-IV-TR (7), who had had an insufficient therapeutic response to ≥2 adequate antidepressant medication trials in the current episode, as per the Antidepressant Treatment History Form (ATHF) (8). All had previously participated in an open-label, single-dose IV ketamine study; had evinced a ≥50% reduction in the severity of their depressive symptoms for at least 24 hours without any
Results
Ten participants received the first IV ketamine infusion. Nine of these participants met response criteria at t+24h (see following text for details) and were eligible for subsequent infusions. One patient missed the fourth infusion.
Discussion
We have presented preliminary data supporting feasibility of repeated-dose IV ketamine in a group of TRD patients who had previously shown a favorable response to a single IV ketamine infusion. Safety, tolerability, and duration of symptom relief during the course of treatment were the criteria established to assess feasibility. Six IV infusions of ketamine administered thrice-weekly over 40 min at a .5 mg/kg dose were well-tolerated. No patient reported greater than mildly bothersome side
References (24)
Glutamate and schizophrenia: Phencyclidine, N-methyl-d-aspartate receptors, and dopamine–glutamate interactions
Int Rev Neurobiol
(2007)- et al.
Antidepressant effects of ketamine in depressed patients
Biol Psychiatry
(2000) - et al.
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression
Biol Psychiatry
(2009) - et al.
Daily process methodology for measuring earlier antidepressant response
Contemp Clin Trials
(2008) - et al.
Clinical and sensorimotor gating effects of ketamine in normals
Neuropsychopharmacology
(2001) - et al.
Long-term outcome of patients who receive ketamine during research
Biol Psychiatry
(2001) - et al.
Ketamine in adults: What emergency physicians need to know about patient selection and emergence reactions
Acad Emerg Med
(2000) - et al.
Interactive effects of subanesthetic ketamine and haloperidol in healthy humans
Psychopharmacology
(1999) - et al.
Potentiation of low dose ketamine effects by naltrexone: Potential implications for the pharmacotherapy of alcoholism
Neuropsychopharmacology
(2006) - et al.
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
Arch Gen Psychiatry
(2006)
Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P)
The definition and meaning of treatment-resistant depression
J Clin Psychiatry
Cited by (578)
Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression
2024, Journal of Affective DisordersAntidepressant effects of dexmedetomidine compared with ECT in patients with treatment-resistant depression
2024, Journal of Affective DisordersA molecular perspective on mGluR5 regulation in the antidepressant effect of ketamine
2024, Pharmacological ResearchA systematic review of the incidence of medical serious adverse events in sub-anesthetic ketamine treatment of psychiatric disorders
2024, Journal of Affective DisordersSex-Specific Alterations in Spatial Memory and Hippocampal AKT-mTOR Signaling in Adult Mice Pre-exposed to Ketamine and/or Psychological Stress During Adolescence
2024, Biological Psychiatry Global Open Science